• Hunter Capital RTO 1’s third-quarter 2026 pretax loss narrowed 54% year-over-year to SEK 59,000.
• Net sales remained nil for the quarter, while cash totaled SEK 504,000 at September 30.
• Positive results from ResoTher Pharma’s RTP-026 phase 2a trial fulfilled a key condition for the planned reverse acquisition.
• The acquisition letter of intent was extended to December 31, 2026; securing financing remains a key requirement for completing the transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hunter Capital RTO 1 AB (publ) published the original content used to generate this news brief via Cision (Ref. ID: 202610221801BITN____UKPR__SV_20261022-BIT-8850-0) on October 22, 2026, and is solely responsible for the information contained therein.